{"prompt": "['4.4.1', 'Permitted Therapy', 'Patients are permitted to use the following therapies during the study:', 'Adjuvant hormone therapy for breast cancer', 'Adjuvant radiotherapy for breast cancer', 'Contraception: acceptable methods of contraception must be used when the female', 'patient is of childbearing potential (i.e. is post-menarchal, has not reached a post-', 'menopausal state [post-menopausal defined as 12 continuous months of amenorrhea', 'with no identified cause other than menopause], and has not undergone surgical', 'sterilization [removal of ovaries and/or uterus]). Acceptable methods of contraception are', 'described in Section 5.1.3.', 'H1-receptor or H2-receptor antagonists (e.g., diphenhydramine, cimetidine)', 'Cardiovascular medications including angiotensin-converting enzyme (ACE) inhibitors,', 'angiotensin receptor blockers, beta blockers, calcium channel blockers and diuretics,', 'beta blockers, calcium channel blockers, digoxin, thrombocyte aggregation inhibitors', 'Analgesics / anti-inflammatories (e.g., paracetamol /acetaminophen, meperidine,', 'opioids)', 'Short-term use of corticosteroids to treat or prevent allergic or infusion reactions are', 'allowed, however, the dose must not exceed > 20 mg/day of dexamethasone (or', 'equivalent) for > 7 consecutive days.', 'Standard therapies for pre-existing medical conditions and medical or surgical', 'complications', 'Any medication intended solely for supportive care (e.g., analgesics, antidiarrheals,', \"antidepressants) at the investigator's discretion\", \"Blood transfusions at the investigator's discretion\", 'Gonadotropin-releasing hormone agonists for fertility preservation', 'Vitamin and mineral supplements', 'Bone density modifying agents (to be used in accordance with the approved labelled', 'indication and/or nationally recognized treatment guidelines)', 'Any other medication not included in the list of prohibited medications', \"In general, investigators should manage a patient's care with supportive therapies as\", 'clinically indicated, per institutional standard practice. Patients who experience infusion-', 'associated symptoms may be treated symptomatically with acetaminophen, ibuprofen,', 'diphenhydramine, and/or H2-receptor antagonists (e.g., famotidine, cimetidine), or equivalent', 'medications per institutional standard practice. Serious infusion-associated events', 'manifested by dyspnoea, hypotension, wheezing, bronchospasm, tachycardia, reduced', 'oxygen saturation, or respiratory distress should be managed with supportive therapies as', 'clinically indicated (e.g., supplemental oxygen and 2-adrenergic agonists).', '4.4.2', 'Cautionary Therapy', 'Concomitant use of herbal therapies is not recommended because their PK, safety profiles,', 'and potential drug-drug interactions are generally unknown. However, herbal therapies not', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '49 / Protocol MO40628, Version 12']['intended for the treatment of cancer may be used during the study at the discretion of the', 'investigator.', '4.4.3', 'Prohibited Therapy', 'Use of the following concomitant therapies is prohibited as described below:', 'Any investigational therapy or agent (other than protocol-mandated study treatment) is', 'prohibited within 28 days prior to initiation of study treatment and during study treatment', 'Any anti-cancer treatment other than adjuvant hormone treatment, adjuvant radiotherapy', 'or bone density modifying treatment', 'Regular systemic treatment with steroids', 'Short-term corticosteroid to treat and prevent allergic or infusion reactions are allowed', 'however the dose must not exceed > 20 mg/day of dexamethasone (or equivalent) for', '> 7 consecutive days.', 'Any systemically active oral, injected, or implanted hormonal method of contraception', '(see Section 5.1.3 for acceptable contraception methods) except for progesterone-', 'coated IUDs that had been previously implanted', 'Hormone-replacement therapy', 'Use of erythropoiesis-stimulating agents (e.g., erythropoietin)', 'Herbal remedies initiated for cancer treatment. Other herbal remedies are discouraged', 'but permitted and must be reported on the appropriate eCRF.', 'Topical oestrogens (including any intra-vaginal preparations), megestrol acetate, and', 'selective ER modulators used with prophylactic intent are prohibited', 'Postmenopausal women with significant vaginal discomfort associated with anti-', 'oestrogen therapy may be considered for intermittent use of low-dose topical oestrogens', 'if non-prescription methods are unsuccessful at ameliorating symptoms.', '4.5', 'STUDY ASSESSMENTS', 'The Schedule of Activities describing study assessments and collection procedures is', 'provided in Appendix 1. Please refer to the Schedule of Activities for frequency and timing', 'of study activities. All study activities must be documented and must be performed as', 'outlined in the Schedule of Activities.', 'Patients will be closely monitored for safety and tolerability throughout the study. Patients', 'should be assessed for toxicity prior to each study treatment; dosing will occur only if clinical', 'assessments and local laboratory test values are acceptable.', '4.5.1', 'Informed Consent Forms and Screening Log', 'Written informed consent for participation in the study must be obtained before performing', 'any study-related procedures. Results of standard-of-care tests or examinations performed', 'prior to obtaining informed consent but within 28 or 7 days of randomization (as indicated)', 'may be used; such tests do not need to be repeated for screening. Informed Consent Forms', 'for enrolled patients and for patients who are not subsequently enrolled will be maintained at', 'the study site.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '50 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}